SIRT5 and metabolic syndrome: Indeed, SIRT5 inhibition by MC3482 might offer a novel pharmacological strategy to be considered in metabolic and cardiovascular rehabilitation programs to improve quality of life of obese subjects with T2D and metabolic syndrome.